Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

REMDESIVIR vs REPOTRECTINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

REMDESIVIR vs REPOTRECTINIB: Safety Overview

Metric REMDESIVIR REPOTRECTINIB
Total FAERS Reports 10,501 187
Deaths Reported 2,729 27
Death Rate 26.0% 14.4%
Hospitalizations 2,556 48
Average Patient Age 61.7 yrs 60.8 yrs
% Female Patients 39.8% 61.1%
FDA Approval Date Oct 22, 2020 Jun 11, 2024
Manufacturer Gilead Sciences, Inc. E.R. Squibb & Sons, L.L.C.
Route INTRAVENOUS ORAL
Marketing Status Prescription Prescription